(RTTNews) - Eli Lilly and Company (LLY) and Morphic Holding (MORF) announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Lilly will commence a tender offer to acquire all outstanding shares of Morphic for a purchase price of $57 per share in cash or an aggregate of approximately $3.2 billion.
Morphic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
